ArticleInternational journal of general medicine2026
Prognostic Value of Platelet-Associated Biomarkers in Nasopharyngeal Carcinoma Patients Received IMRT: A Retrospective Study.
Article in International journal of general medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: This study examines the prognostic significance of platelet-related biomarkers for overall survival (OS) in nasopharyngeal carcinoma (NPC) using Cox proportional hazards and random survival forest (RSF) models, and compares the two modes. Methods: In total, 825 patients with confirmed nasopharyngeal carcinoma were included in this study, and a systematic analysis of their prognostic risk factors was conducted. The patient dataset was divided into training and validation datasets at a ratio of 7:3. A Cox model and RSF model were constructed using clinical data, platelet distribution width (PDW), the ratio of platelet distribution width to platelet count (PDW/P), mean platelet volume (MPV), mean platelet volume‒platelet count ratio (MPV/P) and follow-up survival data. The performances of the two prediction models were evaluated. Results: Multivariate analysis revealed that age (P<0.001, hazard ratios (HR) =1.76, 95% confidence intervals (CI):1.28-2.42), T stage (T3: HR 2.81, 95% CI:1.62-4.83, p<0.001; T4: HR 4.10, 95% CI:1.97-8.52, p<0.001), PDW/P (P= 0.027, HR=1.82, 95% CI:1.07-3.22), and EBV-DNA level (P=0.016, HR=1.51, 95% CI:1.08-2.11) were independent prognostic factors for OS. The RSF model revealed that T stage, stage, the PDW/P and PDW had a notable impact on the model. The Log rank test results showed that when the risk score threshold of the RSF model was 39.63, it had efficacy in differentiating patient groups with significant differences in prognosis. The C-index of the training cohort for the COX model and the RSF model were 0.70 (95% CI: 0.663-0.737) and 0.71 (95% CI, 0.69-0.73) respectively, and 0.62 (95% CI, 0.553-0.681), 0.68 (95% CI:0.62-0.74) in the validation data. Moreover, the decision curve analysis demonstrated that the RSF model provided greater net benefit than the Cox proportional hazards model did. Conclusion: The PDW/P ratio was an independent prognostic factor for OS. The RSF model demonstrated high reliability in predicting clinical outcomes for patients with NPC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.